-
Loading metrics
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
- Z. Ping Lin,
- Yong-Lian Zhu,
- Ying-Chun Lo,
- Jake Moscarelli,
- Amy Xiong,
- Yasmin Korayem,
- Pamela H. Huang,
- Smith Giri,
- Patricia LoRusso,
- Elena S. Ratner
x
- Published: November 16, 2018
- https://doi.org/10.1371/journal.pone.0207399